

Shinichi Tate

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9102613/publications.pdf>

Version: 2024-02-01

27
papers

135
citations

1307594

7
h-index

1281871

11
g-index

27
all docs

27
docs citations

27
times ranked

158
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictors of postoperative pancreatic fistula after splenectomy with or without distal pancreatectomy performed as a component of cytoreductive surgery for advanced ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	2.2	2
2	Bevacizumab-based Salvage Chemotherapy Improves Survival Outcomes for Patients With Brain Metastasis from Ovarian Cancer. <i>Anticancer Research</i> , 2022, 42, 2637-2644.	1.1	3
3	Bevacizumab in first-line chemotherapy to improve the survival outcome for advanced ovarian clear cell carcinoma: A multicenter, retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5502-5502.	1.6	7
4	Tailored-dose chemotherapy with gemcitabine and irinotecan in patients with platinum-refractory/resistant ovarian or primary peritoneal cancer: a phase II trial. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e8.	2.2	3
5	Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin. <i>Cancers</i> , 2021, 13, 640.	3.7	3
6	Introduction of rectosigmoid colectomy improves survival outcomes in early-stage ovarian cancer patients. <i>International Journal of Clinical Oncology</i> , 2021, 26, 986-994.	2.2	2
7	Does aggressive surgery only benefit patients with less advanced ovarian cancer?. <i>Journal of Clinical Oncology</i> , 2021, 39, 5556-5556.	1.6	0
8	Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma. <i>Cancers</i> , 2021, 13, 3177.	3.7	15
9	Surgical Techniques and Outcomes of Colorectal Anastomosis after Left Hemicolectomy with Low Anterior Rectal Resection for Advanced Ovarian Cancer. <i>Cancers</i> , 2021, 13, 4248.	3.7	0
10	Aggressive surgery for advanced ovarian cancer decreases the risk of intraperitoneal recurrence. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1726-1735.	2.2	8
11	Well-trained gynecologic oncologists can perform bowel resection and upper abdominal surgery safely. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e3.	2.2	13
12	Microscopic diseases remain in initial disseminated sites after neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and primary peritoneal cancer. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e34.	2.2	17
13	Effect of bevacizumab in first-line chemotherapy on progression-free survival in advanced ovarian clear cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e18086-e18086.	1.6	0
14	The safety and efficacy of weekly paclitaxel and cisplatin chemotherapy for patients with ovarian cancer who developed carboplatin hypersensitivity reaction in previous chemotherapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6058-6058.	1.6	0
15	Retroperitoneal lymphadenectomy for ovarian cancer with double inferior vena cava. <i>Gynecologic Oncology</i> , 2018, 148, 632-633.	1.4	5
16	Efficacy of soft coagulation in retroperitoneal lymphadenectomy for ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 149, 430-431.	1.4	4
17	Left cardiophrenic lymph node resection for advanced ovarian cancer with adhesion to the thoracic cavity. <i>Gynecologic Oncology</i> , 2018, 151, 390-391.	1.4	0
18	Successful retroperitoneal lymphadenectomy for double inferior vena cava with preoperative assessment using contrast-enhanced and three-dimensional computed tomography. <i>Gynecologic Oncology</i> , 2018, 151, 180-181.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Survival and safety in patients with advanced ovarian cancer undergoing aggressive primary and interval debulking surgery.. <i>Journal of Clinical Oncology</i> , 2018, 36, e17525-e17525.	1.6	0
20	Survival and safety associated with aggressive surgery for stage III/IV epithelial ovarian cancer: A single institution observation study. <i>Gynecologic Oncology</i> , 2017, 147, 73-80.	1.4	19
21	Efficacy of palonosetron plus aprepitant in preventing chemoradiotherapy-induced nausea and emesis in patients receiving daily low-dose cisplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a phase II study. <i>Supportive Care in Cancer</i> , 2016, 24, 4633-4638.	2.2	5
22	Histopathologic tumor spreading in primary ovarian cancer with modified posterior exenteration. <i>World Journal of Surgical Oncology</i> , 2015, 13, 230.	1.9	9
23	Conversion of platinum-taxane resistant to sensitive ovarian cancer with a non-platinum-taxane regimen.. <i>Journal of Clinical Oncology</i> , 2014, 32, e16523-e16523.	1.6	0
24	Microscopic residual carcinoma at interval debulking surgery after neoadjuvant chemotherapy in patients with IIIc/IV MÅ¼llerian carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5567-5567.	1.6	0
25	Bladder function after modified posterior exenteration for primary gynecological cancer. <i>Gynecologic Oncology</i> , 2013, 129, 229-233.	1.4	16
26	Endometrial cancer within tamoxifen-related polyps in patients with breast cancer. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2004, 83, 769-770.	2.8	2
27	Endometrial cancer within tamoxifen-related polyps in patients with breast cancer. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2004, 83, 769-770.	2.8	2